Stay updated on Pembrolizumab and Radiotherapy in Melanoma: Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Radiotherapy in Melanoma: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Radiotherapy in Melanoma: Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Adds a recruitment status notice and new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) while updating the Intervention/Treatment label, reflecting a UI/structure change to the page.
    Difference
    0.7%
    Check dated 2026-06-12T16:52:44.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.5.4 to v3.5.5, indicating a small update to the page's content or formatting.
    Difference
    0.1%
    Check dated 2026-06-05T18:31:48.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Added 'Melanoma' as a related topic and introduced a 'related topics' section featuring MedlinePlus Genetics, providing additional context and external references for readers.
    Difference
    0.2%
    Check dated 2026-05-29T15:26:17.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Added 'Revision: v3.5.4' as the site revision label and removed older items such as 'Melanoma', 'related topics:', 'MedlinePlus Genetics', and 'Revision: v3.5.3' from the page's taxonomy/footer area. This reflects a cleanup of non-essential topics without altering the study content.
    Difference
    0.2%
    Check dated 2026-05-15T06:14:19.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Melanoma and MedlinePlus Genetics were added to the related topics section of the study page, enhancing disease context and links to patient resources.
    Difference
    0.2%
    Check dated 2026-05-01T09:09:46.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The study record reflects an update to outcome-measure definitions and timelines (e.g., RECIST response assessment at 12 weeks and follow-up, PFS/OS timepoints, and safety/tolerability reporting windows) along with corresponding eligibility-criteria text describing required health status and reproductive-contraception requirements. It also updates the record’s “results posted”/last-updated metadata associated with the April 2026 posting.
    Difference
    3%
    Check dated 2026-04-24T05:55:19.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Radiotherapy in Melanoma: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Radiotherapy in Melanoma: Clinical Trial page.